Investing
Bristol Myers wins dismissal of lawsuit over Celgene drugs
© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
NEW YORK (Reuters) – A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers (NYSE:) Squibb Co of defrauding investors who stood to receive $6.4 billion had it won federal approval by specified deadlines for drugs developed by the former Celgene Corp (NASDAQ:).
Read the full article here
-
Investing7 days ago
Moldova breakaway region to face new power cuts on Saturday, officials say By Reuters
-
Investing6 days ago
Reebok Co-Founder Backs Syntilay’s New AI, 3D-Printed Shoe
-
Side Hustles6 days ago
How to Survive High-Demand Seasons Without Losing Customers
-
Side Hustles4 days ago
5 Things That Could Significantly Impact Your Company in 2025
-
Investing5 days ago
NFI Group surge after board reshaped with new appointments, chairperson By Investing.com
-
Side Hustles6 days ago
Shake It Up — Dunkin’ Debuts Star-Backed Winter Menu
-
Side Hustles5 days ago
How Failing 22 Times Paved the Way to My Success
-
Make Money7 days ago
9 Easy Steps to Begin Your Gold Investment Journey